Stephen Mandel’s Boston Scientific BSX Stock Holding History

Stephen Mandel’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-104,655	Closed	-$6.57M	–	37
2026 Q1	$6.57M	Sell	104,655 -97,048	-48%	-$7.76M	0.05%	36
2025 Q4	$19.2M	Buy	+201,703	New	+$19.8M	0.14%	29

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Stephen Mandel's BSX Position: Q2 2026 in Review

Stephen Mandel sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 104,655 shares — an estimated $6.57M sold.

Stephen Mandel first reported a position in BSX in Q4 2025 and held it in 2 quarters. The position peaked at $19.2M in Q4 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Stephen Mandel reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
Stephen Mandel sold 104,655 Boston Scientific shares in Q2 2026, an estimated $6.57M.
Stephen Mandel first reported a position in Boston Scientific in Q4 2025 and held it in 2 quarters.
Stephen Mandel's Boston Scientific position peaked at $19.2M in Q4 2025.
1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Lone Pine Capital's 13F filing for Q2 2026, filed 14 Aug 2026.